Article

AAD House Call: ARQ-151 for Chronic Plaque Psoriasis

Author(s):

Lisa Stein Gold, MD, of Henry Ford Hospital discusses promising phase 2 data for a new PDE4 inhibitor.

Late-breaking data originally planned for presentation the American Academy of Dermatology (AAD) 2020 Scientific Sessions—which has since been cancelled due to concerns raised by the coronavirus (COVID-19) pandemic—show greater potential for investigational drug ARQ-151 (roflumilast cream) as a treatment for chronic plaque psoriasis.

The phase 2b findings, gathered by Linda Stein Gold, MD, of the Henry Ford Hospital, and colleagues, compliment a growing portfolio for the PDE4 inhibitor as a potential treatment for inflammation-based, chronic skin diseases.

In a special edition House Call video interview with HCPLive®, Stein Gold discussed the new findings and what future benefit the topical therapy may have for dermatology.

Related Videos
Phase 3 Findings on Birch Triterpenes for Epidermolysis Bullosa, with Anna Bruckner, MD
3 experts are featured in this series.
3 experts are featured in this series.
Safety Profile, Accessibility of Tapinarof Cream for Atopic Dermatitis, with Adelaide Hebert, MD
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.